Cargando…
The Rising Era of Immune Checkpoint Inhibitors in Myelodysplastic Syndromes
Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases characterized by ineffective hematopoiesis and a wide spectrum of manifestations ranging from indolent and asymptomatic cytopenias to acute myeloid leukemia (AML). MDS result from genetic and epigenetic derangements in clonal cell...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6241340/ https://www.ncbi.nlm.nih.gov/pubmed/30519261 http://dx.doi.org/10.1155/2018/2458679 |
_version_ | 1783371762349637632 |
---|---|
author | Chokr, Nora Patel, Rima Wattamwar, Kapil Chokr, Samer |
author_facet | Chokr, Nora Patel, Rima Wattamwar, Kapil Chokr, Samer |
author_sort | Chokr, Nora |
collection | PubMed |
description | Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases characterized by ineffective hematopoiesis and a wide spectrum of manifestations ranging from indolent and asymptomatic cytopenias to acute myeloid leukemia (AML). MDS result from genetic and epigenetic derangements in clonal cells and their surrounding microenvironments. Studies have shown associations between MDS and other autoimmune diseases. Several immune mechanisms have been identified in MDS, suggesting that immune dysregulation might be at least partially implicated in its pathogenesis. This has led to rigorous investigations on the role of immunomodulatory drugs as potential treatment options. Epigenetic modification via immune check point inhibition, while well established as a treatment method for advanced solid tumors, is a new approach being considered in hematologic malignancies including high risk MDS. Several trials are looking at the efficacy of these agents in MDS, as frontline therapy and in relapse, both as monotherapy and in combination with other drugs. In this review, we explore the utility of immune checkpoint inhibitors in MDS and current research evaluating their efficacy. |
format | Online Article Text |
id | pubmed-6241340 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-62413402018-12-05 The Rising Era of Immune Checkpoint Inhibitors in Myelodysplastic Syndromes Chokr, Nora Patel, Rima Wattamwar, Kapil Chokr, Samer Adv Hematol Review Article Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases characterized by ineffective hematopoiesis and a wide spectrum of manifestations ranging from indolent and asymptomatic cytopenias to acute myeloid leukemia (AML). MDS result from genetic and epigenetic derangements in clonal cells and their surrounding microenvironments. Studies have shown associations between MDS and other autoimmune diseases. Several immune mechanisms have been identified in MDS, suggesting that immune dysregulation might be at least partially implicated in its pathogenesis. This has led to rigorous investigations on the role of immunomodulatory drugs as potential treatment options. Epigenetic modification via immune check point inhibition, while well established as a treatment method for advanced solid tumors, is a new approach being considered in hematologic malignancies including high risk MDS. Several trials are looking at the efficacy of these agents in MDS, as frontline therapy and in relapse, both as monotherapy and in combination with other drugs. In this review, we explore the utility of immune checkpoint inhibitors in MDS and current research evaluating their efficacy. Hindawi 2018-11-01 /pmc/articles/PMC6241340/ /pubmed/30519261 http://dx.doi.org/10.1155/2018/2458679 Text en Copyright © 2018 Nora Chokr et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Chokr, Nora Patel, Rima Wattamwar, Kapil Chokr, Samer The Rising Era of Immune Checkpoint Inhibitors in Myelodysplastic Syndromes |
title | The Rising Era of Immune Checkpoint Inhibitors in Myelodysplastic Syndromes |
title_full | The Rising Era of Immune Checkpoint Inhibitors in Myelodysplastic Syndromes |
title_fullStr | The Rising Era of Immune Checkpoint Inhibitors in Myelodysplastic Syndromes |
title_full_unstemmed | The Rising Era of Immune Checkpoint Inhibitors in Myelodysplastic Syndromes |
title_short | The Rising Era of Immune Checkpoint Inhibitors in Myelodysplastic Syndromes |
title_sort | rising era of immune checkpoint inhibitors in myelodysplastic syndromes |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6241340/ https://www.ncbi.nlm.nih.gov/pubmed/30519261 http://dx.doi.org/10.1155/2018/2458679 |
work_keys_str_mv | AT chokrnora therisingeraofimmunecheckpointinhibitorsinmyelodysplasticsyndromes AT patelrima therisingeraofimmunecheckpointinhibitorsinmyelodysplasticsyndromes AT wattamwarkapil therisingeraofimmunecheckpointinhibitorsinmyelodysplasticsyndromes AT chokrsamer therisingeraofimmunecheckpointinhibitorsinmyelodysplasticsyndromes AT chokrnora risingeraofimmunecheckpointinhibitorsinmyelodysplasticsyndromes AT patelrima risingeraofimmunecheckpointinhibitorsinmyelodysplasticsyndromes AT wattamwarkapil risingeraofimmunecheckpointinhibitorsinmyelodysplasticsyndromes AT chokrsamer risingeraofimmunecheckpointinhibitorsinmyelodysplasticsyndromes |